Chemed (NYSE:CHE) Stock: Insider Kevin Mcnamara Sells 2,000 Shares

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $537.90, for a total transaction of $1,075,800.00. Following the sale, the chief executive officer directly owned 82,220 shares of the company’s stock, valued at approximately $44,226,138. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Chemed Stock Down 2.8%

Shares of CHE traded down $15.21 on Thursday, reaching $533.43. The company’s stock had a trading volume of 137,324 shares, compared to its average volume of 201,328. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The stock has a market capitalization of $6.95 billion, a PE ratio of 25.52, a PEG ratio of 2.03 and a beta of 0.50. The company has a current ratio of 1.11, a quick ratio of 1.08 and a debt-to-equity ratio of 0.27. The firm has a fifty day moving average of $514.63 and a 200-day moving average of $464.29.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.44 by $0.31. The business had revenue of $690.94 million during the quarter, compared to the consensus estimate of $685.04 million. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.27 EPS. Equities analysts predict that Chemed Corporation will post 24.05 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CHE shares. Oppenheimer upped their price target on Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. UBS Group raised their price objective on Chemed from $650.00 to $675.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Wall Street Zen raised shares of Chemed from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 10th. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Bank of America reiterated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Chemed currently has an average rating of “Hold” and an average target price of $603.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Richardson Financial Services Inc. grew its stake in Chemed by 5,700.0% during the third quarter. Richardson Financial Services Inc. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Fulcrum Asset Management LLP lifted its stake in Chemed by 121.9% in the 3rd quarter. Fulcrum Asset Management LLP now owns 71 shares of the company’s stock worth $36,000 after purchasing an additional 39 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Chemed in the 2nd quarter valued at $34,000. Versant Capital Management Inc boosted its holdings in Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after purchasing an additional 75 shares during the period. Finally, Keating Financial Advisory Services Inc. purchased a new position in shares of Chemed during the 2nd quarter valued at $36,000. Institutional investors own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.